160 related articles for article (PubMed ID: 11474633)
1. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
File TM; Schlemmer B; Garau J; Cupo M; Young C;
J Antimicrob Chemother; 2001 Jul; 48(1):67-74. PubMed ID: 11474633
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
Hammerschlag MR
J Antimicrob Chemother; 2001 Nov; 48(5):735. PubMed ID: 11679567
[No Abstract] [Full Text] [Related]
3. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin.
Ball P; Wilson R; Mandell L; Brown J; Henkel T;
J Chemother; 2001 Jun; 13(3):288-98. PubMed ID: 11450888
[TBL] [Abstract][Full Text] [Related]
4. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
5. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
[TBL] [Abstract][Full Text] [Related]
6. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia.
Sokol WN; Sullivan JG; Acampora MD; Busman TA; Notario GF
Clin Ther; 2002 Apr; 24(4):605-15. PubMed ID: 12017405
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections.
Ball P; File TM; Twynholm M; Henkel T
Int J Antimicrob Agents; 2001 Jul; 18(1):19-27. PubMed ID: 11463522
[TBL] [Abstract][Full Text] [Related]
8. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin.
Léophonte P; File T; Feldman C
Respir Med; 2004 Aug; 98(8):708-20. PubMed ID: 15303634
[TBL] [Abstract][Full Text] [Related]
9. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.
Trémolières F; de Kock F; Pluck N; Daniel R
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):447-53. PubMed ID: 9758291
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Patel T; Pearl J; Williams J; Haverstock D; Church D
Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
[TBL] [Abstract][Full Text] [Related]
11. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
Bhavnani SM; Andes DR
Pharmacotherapy; 2005 May; 25(5):717-40. PubMed ID: 15899734
[TBL] [Abstract][Full Text] [Related]
12. Role of gemifloxacin in community-acquired pneumonia.
Tillotson GS
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
O'Doherty B; Dutchman DA; Pettit R; Maroli A
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():73-81. PubMed ID: 9484876
[TBL] [Abstract][Full Text] [Related]
14. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
Yoo BK; Triller DM; Yong CS; Lodise TP
Ann Pharmacother; 2004; 38(7-8):1226-35. PubMed ID: 15187209
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. Trovafloxacin Bronchitis Study Group.
O'Doherty B; Daniel R
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):441-6. PubMed ID: 9758290
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
Klossek JM; Siegert R; Nikolaidis P; Arvis P; Leberre MA;
J Laryngol Otol; 2003 Jan; 117(1):43-51. PubMed ID: 12590855
[TBL] [Abstract][Full Text] [Related]
17. Gemifloxacin for community-acquired pneumonia.
Lode HM; Schmidt-Ionas M; Stahlmann R
Expert Opin Investig Drugs; 2008 May; 17(5):779-86. PubMed ID: 18447602
[TBL] [Abstract][Full Text] [Related]
18. Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections.
File TM; Tillotson GS
Expert Rev Anti Infect Ther; 2004 Dec; 2(6):831-43. PubMed ID: 15566328
[TBL] [Abstract][Full Text] [Related]
19. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group.
File T; Schlemmer B; Garau J; Lode H; Lynch S; Young C
J Chemother; 2000 Aug; 12(4):314-25. PubMed ID: 10949981
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis.
Sethi S; Fogarty C; Fulambarker A
Respir Med; 2004 Aug; 98(8):697-707. PubMed ID: 15303633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
